PORTEC-4a Pathology Review Form

Form 2A – 28 March 2018

Patient trial no.	**Pathology review number**	**Review centre**
|__|__|__|	|__|__|__|__|__|__|__|	……

Histologic classification (1 = endometrioid adenocarcinoma, 2= mixed endometrioid and serous or clear cell cancer (<10% of serous or clear cell component), 3 = mucinous type endometrial cancer, 4=squamous type endometrial cancer, 5 = serous cancer (>10%), 6 = clear cell cancer (>10%), 7 = other type*) *specify:..... |__|(1)

Grade (1 = grade 1; 2 = grade 2; 3 = grade 3, 9 = unknown/not assessable)..... |__|(2)

Myometrial invasion (1 = <50%, 2 = ≥ 50%) ..... |__|(3)

Minimum distance from tumor to serosa at the point of deepest myometrial invasion (mm).. |__|__|.|__|(4)

Growth through serosa (0=no, 1=yes) ..... |__|(5)

Cervical stromal involvement (0=no, 1=yes)..... |__|(6)

FIGO 2009 stage (1 = IA, 2= IB, 3 = II, 4=other*) *please specify other: ..... |__|(7)

ER and PR (0=both negative (<10% expression); 1= ER+ (≥10%)/ PR- (<10%); 2=ER- (<10%)/PR+ (≥10%); 3= both + (≥10%); 4=technical failure)..... |__|(8)

PORTEC-4a MOLECULAR INTEGRATED PROFILE

Lymph-vascular space invasion (LVSI) (0=none/mimic; 1=yes, focal (<3 involved vessels); 2=yes, substantial (>5 involved vessels, or 3-5 involved vessels on more than 1 slide), 3=not evaluable)..... |__|(9)

POLE (0=wild type; 1=pathogenic variant, 2=non-pathogenic variant,3=variant with unknown pathogenicity, 4= not evaluable)..... |__|(10)

P53 expression by **IHC** (0=wild type, 1=abnormal; 2= not evaluable; 3 = ambiguous/uncertain (confirm by sequencing)*; 7 = not performed) ..... |__|(11)

*TP53 mutational status by **NGS or Sanger sequencing** (0=wild type, 1= pathogenic variant; 2=non-pathogenic variant; 3= not evaluable; 4=variant with unknown pathogenicity; 7=not applicable)..... |__|(12)

CTNNB1-exon 3 variant (0=wild type; 1=pathogenic variant; 2=non-pathogenic variant;3=not evaluable).. |__|(13)

L1CAM expression (0=negative; <10% expression; 1= positive; ≥10%,<50% expression; 2=positive; ≥50% expression; 3= not evaluable)..... |__|(14)

Mismatch Repair (MMR) expression (MLH1, PMS2, MSH6, MSH2) by IHC (0=normal nuclear staining of all 4 MMR proteins, 1= loss of 1 or more MMR proteins*; 2= not evaluable) ..... |__|(15)

* if MMR loss: 1=combination MLH1 and PMS2 (*MLH1* methylation test required to exclude LS[#]), 2 = combination MSH6 and MSH2 (LS suspected), 3=individual loss of MSH6 (LS suspected), 4=individual loss of PMS2 (LS suspected), 5=loss of MLH1, PMS2 and MSH6 (*MLH1* methylation test required to exclude LS[#]), 6= other combination, 7= not applicable ..... |__|(16)

[#] if MLH1 loss: 1=confirmed MLH1 promotor hypermethylation, 2=possible Lynch, 3=not performed, 7=not applicable..... |__|(17)

OVERALL OUTCOME OF THE PORTEC-4a INTEGRATED MOLECULAR PROFILE

Overall outcome profile (1=favourable; 2=intermediate; 3=unfavourable)..... |__|(18)

Suspected Lynch-syndrome (LS) (0=no, 1=yes, 3= not evaluated)..... |__|(19)

PLEASE SEND A COPY OF THE REVIEW PATHOLOGY REPORT TO: portec@iknl.nl

Date:…… **Investigator's signature:**……